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It is with great personal pleasure that I present this year’s
recipient of the William Allan Award, Albert de la Cha-
pelle. This prize is the major award of our society and
is granted yearly to a scientist for substantial contri-
butions to human and medical genetics that have been
carried out over a lifetime of scientific and scholarly
inquiry.
Albert de la Chapelle received his M.D. in 1957 at
the University of Helsinki; he then began his clinical
training, becoming board certified in internal medicine
in 1965. His career has been almost exclusively devoted
to research in human genetics. He earned a Ph.D. in
human genetics at the University of Helsinki in 1962,
received postdoctoral training with Paul Marks in bio-
chemistry at Columbia University in 1966–1968, and
training in biochemical genetics at the MRC Biochemical
Genetics Unit in London in 1974. He was one of four
scientists who founded the subspecialty of medical ge-
netics in Finland. He was the first professor of medical
genetics in Finland and was chairman of the Department
of Medical Genetics at the University of Helsinki, be-
ginning in 1974. Since 1997, Dr. de la Chapelle has been
the Charlotte and Leonard Immke Chair of Cancer Ge-
netics at the Ohio State University, where he directs the
Human Cancer Genetics Program.
The cytogenetics of human sex determination and dif-
ferentiation was the focus of his doctoral thesis. He
showed that a high proportion of patients with Turner
syndrome were mosaics and that these cases displayed
milder and somewhat atypical clinical features compared
with the standard 45,X cases. In 1964, he described the
first example of a human male with an entirely normal-
appearing female karyotype 46,XX (de la Chapelle et
al. 1964). In a series of papers over the next 20 years,
he defined the epidemiology, cytogenetics, genealogy,
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and clinical features of XX males. The etiology of male-
ness began to be clarified when he presented the first
concrete evidence of an interchange between the X and
Y chromosomes (de la Chapelle et al. 1984). This was
followed by the detection of Y-specific sequences in some
XX males (Page et al. 1985) and the description of the
pseudoautosomal region near the end of the short arms
of the X and Y chromosomes (Simmler et al. 1985).
Finally, he showed that the Y-specific sequences present
in XX males were indeed located near the telomeric end
of the short arm of one X chromosome (Andersson et
al. 1986) and occurred as a result of exchange during
paternal meiosis (Page et al. 1987). These findings pro-
vided the groundwork for the subsequent cloning of the
testis-determining factor, SRY, by others.
I have known Albert for more than 30 years. I first
met him at the International Congress of Human Ge-
netics in Mexico City in 1976. We both had published
papers on chromosome abnormalities in human leuke-
mia at a time when there were very few cytogeneticists
interested in this area of research. He described trisomy
for a group “C” chromosome in leukemia (de la Cha-
pelle et al. 1970); showed that the extra chromosome
was number 8 (de la Chapelle et al. 1972); and used this
information to map a gene, glutathione reductase, to this
chromosome (de la Chapelle et al. 1976). It was later
shown that trisomy for chromosome 8 is the most com-
mon numerical abnormality in acute myeloid leukemia
(AML) and confers a poor prognosis. Albert and I de-
cided that enough information was available to consider
having an international workshop on the types of chro-
mosome abnormalities seen in human leukemia and to
investigate some of their clinical implications. He was
chairman of the 6th International Chromosome Con-
ference, first organized by Professor Darlington in Ox-
ford, and the meeting was to be held in Helsinki in 1977.
It seemed appropriate, then, for this conference to be
the occasion for inviting individuals from around the
world who had published on the chromosome pattern
in human leukemia. The workshop was held in the fall
of 1977; it was the first of a series of workshops on
chromosomes in leukemia that each developed impor-
tant information about the frequency and clinical im-
plications of chromosome abnormalities in various sub-
types of leukemia and lymphoma (First International
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Workshop on Chromosomes in Leukaemia 1978). The
conferences were held in Europe and Japan, as well as
the United States. These workshops have served as mod-
els of international collaboration by providing state-of-
the-art correlations between cytogenetic findings and
clinical parameters, such as prognosis in human leuke-
mia and lymphoma. Many of these studies have had a
significant impact, not only on the diagnosis and clas-
sification of leukemia and lymphoma but also on the
treatment selected for patients. They have provided a
model for many subsequent workshops focusing on a
particular relatively rare disease.
Dr. de la Chapelle’s career has been characterized by
his uncanny ability to be involved in a scientific problem
at the right time and right place, but most importantly,
to have acquired the requisite skills to pursue ground-
breaking research. In the early 1980s, his interest began
to shift to human disease genes. What better place to
study rare diseases and discover new genes than Finland?
The Finnish population is a typical founder population
that displays important special features. In these pop-
ulations, enrichment of random alleles typically occurs
as a result of founder effect, population bottlenecks, and
genetic drift (de la Chapelle 1993). In Finland, this has
resulted in the accumulation of approximately 34 he-
reditary disorders, mostly autosomal recessive (de la
Chapelle and Wright 1998). In the 1980s, not a single
one of these disorders had been genetically characterized.
Mapping, cloning, and characterizing the genes for these
disorders became the main focus of the de la Chapelle
laboratory. Today most of these diseases have been mo-
lecularly characterized, to some degree at least, including
the mapping and cloning of the gene and detection of
its mutations (reviewed in de la Chapelle and Wright
1998). It is noteworthy that among the disorders char-
acterized so far, approximately half have been elucidated
by the de la Chapelle group. Highlights include the first
mapping by genomewide search for linkage of one of
the “Finnish” recessive disorders, diastrophic dysplasia,
in 1990. The gene product, DTDST, turned out to be a
sulfate transporter affecting the growth of cartilage
(Ha¨stbacka et al. 1994). Other highlights are the de-
scription of and gene detection in two previously un-
recognized, novel “Finnish” disorders, hereditary hypo-
gonadotropic gonadal failure caused by mutations in the
follicle-stimulating hormone-receptor gene (Aittoma¨ki et
al. 1995) and progressive epilepsy with mental retarda-
tion caused by mutations in the CLN8 gene (Ranta et
al. 1999). More recent discoveries include the fact that
cartilage hair hypoplasia was due to mutations in an
untranslated gene, RMRP, encoding the RNA compo-
nent of a ribonuclease MRP, active both in the nucleolus
and in the mitochondria (Ridanpa¨a¨ et al. 2001). This
intriguing finding is being followed up by mouse mod-
eling in the de la Chapelle laboratory. Further, in Usher
syndrome type 3, a previously unknown gene with two
transmembrane domains was found to be mutated (Joen-
suu et al. 2001). This gene appears to bear no relation-
ship to the five previously characterized genes for other
forms of Usher syndrome; thus, in all likelihood, it will
eventually broaden our understanding of signaling
mechanisms in the retina and cochlea. In his studies of
these “Finnish” disorders, Dr. de la Chapelle has been
one of the pioneers in utilizing linkage-disequilibrium
analysis in the positional cloning of genes (de la Chapelle
1993; de la Chapelle and Wright 1998). This method is
now one of the cornerstones of gene detection world-
wide, not only in Mendelian disorders but also in multi-
factorial disease, including cancer. The mapping, clon-
ing, and characterization of these disease genes by Dr.
de la Chapelle and his former students have already had
major clinical consequences. First, their work allows pre-
cise molecular diagnosis, often with prognostic impli-
cations. Second, it allows carrier detection and risk as-
sessment in affected families. Third, it is an entre´e to
our understanding of disease mechanisms, which, in
turn, is a prerequisite for devising effective therapeutic
strategies.
One of the most recent and far-reaching examples of
his “nose” for innovative research is his work in colon
cancer. The painstaking work of Henry Lynch, who
gathered pedigrees of families with cancer, raised intrigu-
ing questions. In the 1980s, the existence of major hered-
itary forms of the common cancers was controversial.
De la Chapelle’s breakthrough findings in hereditary
nonpolyposis colon cancer (HNPCC) initiated a new era
in hereditary cancer research preceding similar discov-
eries in, for example, breast and prostate cancer (Aal-
tonen et al. 1993). Because this research is the focus of
Dr. de la Chapelle’s lecture, I will not summarize the
results here.
This quick review points out just a few of Albert’s
most remarkable accomplishments. They are notable for
their innovative qualities and for their breadth. Albert
is truly an international human geneticist! In addition
to being a regular attendee at ASHG meetings, he is also
a member of the European Society of Human Genetics,
of which he was president in 1993–1994. Albert has
long worked for closer interactions between the Amer-
ican and European societies on a number of scientific,
political, and ethical issues.
As you would expect, he has received numerous hon-
ors and awards in Finland and elsewhere in recognition
of his research accomplishments. In Finland, he is a
member and honorary member of its senior Academy
of Sciences and Letters. He also is a fellow (“1 of 12”)
of the Academy of Finland. He was the first M.D. ever
to receive this highest scientific honor of the country. He
holds an honorary doctorate at the University of Oulu
and the University of Uppsala. Among his other awards
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are the Anders Jahre Prize for Medicine (University of
Oslo) and the Phoenix-Anni Verdi Award for Genetic
Research (Italy). He is a foreign member of the Royal
Swedish Academy of Sciences and of the National Acad-
emy of Sciences, U.S.A.
It is my great pleasure to introduce Dr. de la Chapelle,
who certainly follows in the footsteps of Dr. William
Allan, acknowledged as the first physician who was in-
volved in extensive genetic research in the United States.
The title of his lecture is, “Inherited Human Diseases:
Challenges, Victories, Disappointments.”
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